The included case reports and other studies yielded additional insights into the potential therapeutic utility of SGLT2 inhibitors for managing hypomagnesemia, extending their benefit to patients who may not exhibit overt urinary magnesium wasting. The gene discussed is SLC5A2; the disease is familial primary hypomagnesemia.